Patent cliff fears drive through 2020’s second largest pharma deal
Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.